Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early- stage melanoma patients

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3238-3244

  Bostick, Peter J ^a   Morton, Donald L ^a   Turner, Roderick R ^a   Huynh, Kelly T ^a   Wang, He Jing ^a   Elashoff, Robert ^a   Essner, Richard ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032887957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3238     Document Type: Article

References (28)

1. Buzaid AC, Tinoco LA, Jendiroba D, et al: Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 13:2361-2368, 1995
2. Morton DL, Wanek L, Nizze JA, et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491-499, 1991
3. Kirkwood JM: Adjuvant IFNα2 therapy of melanoma. Lancet 351:1901-1903, 1998
4. Hoon DS, Okamoto T, Wang HJ, et al: Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 16:1430-1437, 1998
5. Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392-399, 1992
6. Cochran AJ, Wen DR, Herschman HR, et al: Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 34:159-163, 1984
7. Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280:1410-1415, 1998
8. Smith B, Selby P, Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227-1229, 1991
9. Doi F, Chi DDJ, Charuworn BB, et al: Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 65:454-459, 1996
10. Kuo CT, Bostick PJ, Irie RF, et al: Assessment of messenger RNA of β1 → 4-N-acetylgalactosaminyltransferase as a molecular marker for metastatic melanoma. Clin Cancer Res 4:411-418, 1998
11. Jung FA, Buzaid AC, Ross MI, et al: Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 15:2826-2831, 1997
12. Kunter U, Buer J, Probst M, et al: Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 88:590-594, 1996
13. Mellado B, Colomer D, Castel T, et al: Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 14:2091-2097, 1996
14. Hoon DS, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-2116, 1995
15. Morton DL, Wen DR, Foshag LJ, et al: Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 11:1751-1756, 1993
16. Morton DL, Wen D-R, Cochran AJ: Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1:247-259, 1992
17. Sarantou T, Chi DD, Garrison DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
18. Bostick PJ, Chatterjee S, Chi DD, et al: Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632-2640, 1998
19. Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997
20. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer-Verlag, 1997
21. Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244, 1996
22. Livingston P: Ganglioside vaccines with emphasis on GM2. Semin Oncol 25:636-645, 1998
23. Ludwig Trial, International Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 335:1565-1568, 1990
24. Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255-266, 1996
25. Bostick P, Essner R, Glass E, et al: Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 134:43-49, 1999
26. Leong SP, Steinmetz I, Habib FA, et al: Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 132:666-673, 1997
27. Karakousis CP, Velez AF, Spellman JE, et al: The technique of sentinel node biopsy. Eur J Surg Oncol 22:271-275, 1996
28. Carson KF, Wen DR, Li PX, et al: Nodal nevi and cutaneous melanomas. Am J Surg Pathol 20:834-840, 1996